Research Article
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma
Table 1
Patients characteristics at chemotherapy when starting ifosfamide.
| Patients characteristics | |
| Age, years | | Median | 33 | Range | 31–75 |
| Histopathological diagnosis | | Round cell myxoid liposarcoma (high grade) | 7 (63%) | Classical myxoid liposarcoma (low grade) | 4 (37%) |
| Metastatic disease at diagnosis | 2 (18%) | Localized disease at diagnosis | 9 (82%) |
| Adjuvant chemotherapy | | Y | 8 (73%) | N | 3 (27%) |
| Adjuvant radiotherapy | | Y | 7 (64%) | N | 4 (36%) |
| Number of sites involved | | Median | 2 | Range | 1–3 |
| Local relapse | 4 (36%) |
| Metastatic sites | | Lung | 8 (73%) | Abdominal cavity | 7 (64%) | Bone | 1 (9%) | Soft Tissue | 1 (9%) |
| Number of prior chemotherapy regimens | | 0 | 1 (10%) | 1 | 5 (45%) | 2 | 3 (27%) | 3 | 2 (18%) |
| Prior chemotherapy | | Anthracycline ± Ifosfamide | 11 (100%) | Trabectedin | 3 (27%) | Pemetrexed | 1 (10%) | Liposomal doxorubicin | 1 (9%) | Unknown | 2 (18%) |
| High-dose ifosfamide infusion | | Elastomeric pump | 11 (100%) |
| Number of ifosfamide courses | | Median | 3 | Range | (2–7) |
|
|